Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013142300 - JCV NEUTRALIZING ANTIBODIES

Publication Number WO/2013/142300
Publication Date 26.09.2013
International Application No. PCT/US2013/031853
International Filing Date 15.03.2013
IPC
C07K 16/08 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
C07K 16/084
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
08against material from viruses
081from DNA viruses
084Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
C07K 2317/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
C07K 2317/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
24containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
C07K 2317/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
40characterized by post-translational modification
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applicants
  • BIOGEN IDEC MA INC. [US]/[US]
Inventors
  • SIMON, Kenneth
  • CAMERON, Thomas
  • RUSHE, Mia
  • CARAVELLA, Justin
  • KAYNOR, George, Campbell
Agents
  • SPEK, Erik, J.
Priority Data
61/613,24920.03.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) JCV NEUTRALIZING ANTIBODIES
(FR) ANTICORPS DE NEUTRALISATION DIRIGÉS CONTRE LE JVC
Abstract
(EN)
In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.
(FR)
La présente invention concerne, dans un aspect, des anticorps de neutralisation dirigés contre le JVC et des procédés de traitement de la LEMP.
Latest bibliographic data on file with the International Bureau